Xtl Biopharmaceuticals (XTLB) Cash from Investing Activities (QoQ) (2010 - 2015)
Xtl Biopharmaceuticals (XTLB) Cash from Investing Activities (QoQ) (2010 - 2015) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 14.29% |
| Sep 30, 2015 | -350.00% |
| Dec 31, 2014 | 344.83% |
| Sep 30, 2014 | -78.44% |
| Jun 30, 2014 | 92.83% |
| Mar 31, 2014 | 129.52% |
| Dec 31, 2013 | -124.99% |
| Sep 30, 2013 | 126,166.67% |
| Jun 30, 2013 | -100.60% |
| Mar 31, 2013 | 168.86% |
| Dec 31, 2012 | -555.63% |
| Sep 30, 2012 | 109.87% |
| Jun 30, 2012 | -265.24% |
| Mar 31, 2012 | 199.80% |
| Dec 31, 2011 | -755.33% |
| Sep 30, 2011 | 552.17% |
| Jun 30, 2011 | 101.24% |
| Mar 31, 2011 | -3,758.33% |
| Dec 31, 2010 | -100.00% |
| Sep 30, 2010 | -380.00% |